Search

Your search keyword '"Jäger, Ulrich"' showing total 455 results

Search Constraints

Start Over You searched for: Author "Jäger, Ulrich" Remove constraint Author: "Jäger, Ulrich" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
455 results on '"Jäger, Ulrich"'

Search Results

1. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

2. Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

7. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

8. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

9. Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma

10. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL

11. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

12. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle

13. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia

14. UGT2B17 modifies drug response in chronic lymphocytic leukaemia

16. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

17. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

18. A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells.

19. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

20. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

21. Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

22. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia

23. Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma

25. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL

27. The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma

28. N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia

30. Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine

32. Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

33. YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update

34. Abstract 5186: Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial

35. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

37. The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies

46. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

47. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

48. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

49. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia

50. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

Catalog

Books, media, physical & digital resources